The 20S Proteasome β2 Inhibitors belong to a distinctive chemical class of compounds that exert their influence on the enzymatic activity of the β2 subunit within the 20S proteasome complex. The 20S proteasome is an essential multicatalytic enzyme complex found in eukaryotic cells, responsible for the selective degradation of intracellular proteins. Within this complex, the β2 subunit plays a crucial role in mediating the proteolytic activity, as it harbors the catalytic centers that cleave peptide bonds. The inhibitors targeting this specific subunit act by modulating the proteasomal degradation process, thereby influencing protein turnover and cellular homeostasis. Structurally, these inhibitors possess distinctive molecular features that enable them to interact with the active site of the β2 subunit. These interactions can either interfere with the substrate recognition or disrupt the catalytic mechanism, leading to the accumulation of specific proteins targeted for degradation. The binding affinity of these inhibitors to the β2 subunit is crucial for their inhibitory activity and can be influenced by various chemical modifications within their scaffold.
The development and refinement of 20S Proteasome β2 Inhibitors have been a subject of intense research in molecular pharmacology. Researchers have sought to elucidate the intricate mechanisms of proteasomal degradation and exploit the potential of these inhibitors for various applications. Their detailed characterization at the molecular level has provided insights into the intricate interplay between the inhibitor structure and its activity, shedding light on the potential for designing highly selective and potent inhibitors. By understanding the molecular basis of these inhibitors' actions, scientists aim to expand the arsenal of tools available for probing cellular processes and potentially devising strategies for modulating protein levels in a controlled manner. In conclusion, the 20S Proteasome β2 Inhibitors constitute a significant class of compounds that hold promise for manipulating protein degradation processes within cells. Their unique structural features and interactions with the proteasome complex provide a platform for understanding and influencing cellular protein turnover dynamics.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor. It is used primarily for multiple myeloma and certain types of lymphoma. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
Ixazomib is a proteasome inhibitor investigated for multiple myeloma. It is administered in combination with other drugs. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
Oprozomib is an investigational proteasome inhibitor being studied for various cancers. | ||||||
Delanzomib, free base | 847499-27-8 | sc-396774 sc-396774A | 5 mg 10 mg | $160.00 $300.00 | ||
Delanzomib is another experimental proteasome inhibitor under investigation for its anti-cancer properties. | ||||||